<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963608</url>
  </required_header>
  <id_info>
    <org_study_id>RSINETE</org_study_id>
    <nct_id>NCT04963608</nct_id>
  </id_info>
  <brief_title>RWS of Inetetamab HER2 Positive Advanced Breast Cancer</brief_title>
  <official_title>Real World Study of Inetetamab HER2 Positive Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhiyong Yu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-Interventional study will describe and analyze the clinical use of Inetetamab in&#xD;
      clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidences of adverse events and toxicities</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HER2-positive Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>non-interventional study</arm_group_label>
    <description>Her2 positive ABC patients who have received Inetetamab in the metastatic setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inetetamab</intervention_name>
    <description>8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days</description>
    <arm_group_label>non-interventional study</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HER2+ advanced breast cancer patients whose treatment decision with Inetetamab has been&#xD;
        made by their physician and who meet the eligibility criteria will be invited to&#xD;
        participate in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with stage IV breast cancer&#xD;
&#xD;
          2. Patients with HER2 positive status&#xD;
&#xD;
          3. Patients that received Inetetamab&#xD;
&#xD;
          4. Patients that began Inetetamab therapy prior to June 30, 2021.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients treated with an investigational anticancer agent Inetetamab&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhiyong yu</last_name>
    <phone>86-13355312277</phone>
    <email>drzhiyongyu@aliyun.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 11, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Zhiyong Yu</investigator_full_name>
    <investigator_title>Chief of breast department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The results of this retrospective observational study will not be formally documented in a Clinical Study Report. Coded patient-level data will be shared with the sponsor.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

